GSK Lobs False Ad Suit At Teva Over Axed Wellbutrin Generic

Law360, New York (February 11, 2013, 1:19 PM EST) -- GlaxoSmithKline LLC on Friday launched a false advertising suit in Pennsylvania federal court accusing Teva Pharmaceuticals USA Inc. of costing it hundreds of millions of dollars by promoting a generic version of antidepressant Wellbutrin that was discontinued after its effectiveness came into question.

The complaint, filed four months after Teva and Impax Laboratories Inc. yanked 300-milligram tablets of Budeprion XL from pharmacy shelves, accuses the drugmakers of concealing crucial information and stonewalling attempts to investigate reports that their medicine wasn’t yielding the same results as Wellbutrin....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

GLAXOSMITHKLINE LLC v. TEVA PHARMACEUTICALS USA, INC.


Case Number

2:13-cv-00726

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Other Statutory Actions

Judge

EDUARDO C. ROBRENO

Date Filed

February 7, 2013

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.